APP-C31: an intracellular promoter of both metal-free and metal-bound amyloid-β40 aggregation and toxicity in Alzheimer's disease

Cited 5 time in scopus
Metadata Downloads
Title
APP-C31: an intracellular promoter of both metal-free and metal-bound amyloid-β40 aggregation and toxicity in Alzheimer's disease
Author(s)
E Nam; Y Lin; J Park; H Do; J Han; Bohyeon Jeong; Subin Park; Da Yong Lee; M Kim; J Han; M H Baik; Y H Lee; M H Lim
Bibliographic Citation
Advanced Science, vol. 11, no. 4, pp. 2307182-2307182
Publication Year
2024
Abstract
Intracellular C-terminal cleavage of the amyloid precursor protein (APP) is elevated in the brains of Alzheimer's disease (AD) patients and produces a peptide labeled APP-C31 that is suspected to be involved in the pathology of AD. But details about the role of APP-C31 in the development of the disease are not known. Here, this work reports that APP-C31 directly interacts with the N-terminal and self-recognition regions of amyloid-β40 (Aβ40) to form transient adducts, which facilitates the aggregation of both metal-free and metal-bound Aβ40 peptides and aggravates their toxicity. Specifically, APP-C31 increases the perinuclear and intranuclear generation of large Aβ40 deposits and, consequently, damages the nucleus leading to apoptosis. The Aβ40-induced degeneration of neurites and inflammation are also intensified by APP-C31 in human neurons and murine brains. This study demonstrates a new function of APP-C31 as an intracellular promoter of Aβ40 amyloidogenesis in both metal-free and metal-present environments, and may offer an interesting alternative target for developing treatments for AD that have not been considered thus far.
ISSN
2198-3844
Publisher
Wiley
Full Text Link
http://dx.doi.org/10.1002/advs.202307182
Type
Article
Appears in Collections:
Division of A.I. & Biomedical Research > Biotherapeutics Translational Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.